INSYS Therapeutics Confirms Completion of Founder’s Independent Trust


PHOENIX, March 01, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that company founder John N. Kapoor, Ph.D., has completed the previously announced formation of an independently controlled trust related to his ownership stake in the company. The trust has been publicly filed with the Securities and Exchange Commission by the company on a Current Report on Form 8-K.

About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need. 

CONTACT:Corporate CommunicationsInvestor Relations
 Joe McGrathJackie Marcus or Chris Hodges
 INSYS TherapeuticsAlpha IR Group
 480-500-3101312-445-2870
 jmcgrath@insysrx.comINSY@alpha-ir.com